S&P 500   5,088.80
DOW   39,131.53
QQQ   437.52
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.52
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.52
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
S&P 500   5,088.80
DOW   39,131.53
QQQ   437.52
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Analysts boosted Snowflake stock, big firms are buying now
First it was Tyson stock, now this food company is set to rally
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
6 reasons to buy Teva Pharmaceuticals stock sooner than later
3 Chinese stocks poised for rebound
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

$981.20
+16.31 (+1.69%)
(As of 02/23/2024 06:55 PM ET)
Today's Range
$969.15
$985.64
50-Day Range
$841.79
$981.20
52-Week Range
$684.80
$985.64
Volume
439,600 shs
Average Volume
535,895 shs
Market Capitalization
$107.70 billion
P/E Ratio
28.24
Dividend Yield
N/A
Price Target
$939.05

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
4.3% Downside
$939.05 Price Target
Short Interest
Healthy
1.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
0.40mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$10.78 M Sold Last Quarter
Proj. Earnings Growth
9.34%
From $38.53 to $42.13 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.07 out of 5 stars

Medical Sector

172nd out of 935 stocks

Pharmaceutical Preparations Industry

75th out of 432 stocks

REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
REGN Feb 2024 957.500 put
REGN Feb 2024 965.000 put
REGN Feb 2024 952.500 call
2 No-Brainer Biotech Stocks to Buy Right Now
REGN Mar 2024 910.000 put
REGN Mar 2024 1090.000 call
REGN Mar 2024 1010.000 call
REGN Mar 2024 820.000 put
REGN Apr 2024 1005.000 call
REGN Mar 2024 952.500 call
REGN Feb 2024 700.000 put
REGN Feb 2024 1000.000 call
REGN Feb 2024 930.000 put
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/02/2024
Today
2/25/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
13,450
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$939.05
High Stock Price Target
$1,110.00
Low Stock Price Target
$680.00
Potential Upside/Downside
-4.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
24 Analysts

Profitability

Net Income
$3.95 billion
Pretax Margin
32.01%

Debt

Sales & Book Value

Annual Sales
$13.12 billion
Cash Flow
$43.26 per share
Book Value
$236.63 per share

Miscellaneous

Free Float
100,070,000
Market Cap
$107.70 billion
Optionable
Optionable
Beta
0.11

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Regeneron Pharmaceuticals was last updated on Wednesday, February 21, 2024 at 2:25 PM.














REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

24 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 5 hold ratings and 18 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

24 Wall Street research analysts have issued 1 year target prices for Regeneron Pharmaceuticals' stock. Their REGN share price targets range from $680.00 to $1,110.00. On average, they predict the company's stock price to reach $939.05 in the next twelve months. This suggests that the stock has a possible downside of 4.3%.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2024?

Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of the year. Since then, REGN shares have increased by 11.7% and is now trading at $981.20.
View the best growth stocks for 2024 here
.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 1,250,000 shares, an increase of 16.8% from the January 15th total of 1,070,000 shares. Based on an average daily trading volume, of 576,700 shares, the short-interest ratio is currently 2.2 days.
View Regeneron Pharmaceuticals' Short Interest
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings results on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The biopharmaceutical company earned $3.43 billion during the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a trailing twelve-month return on equity of 17.61%. The business's quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the business earned $10.96 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (8.11%), Capital World Investors (4.71%), Capital International Investors (2.68%), Dodge & Cox (2.16%), Putnam Investments LLC (1.11%) and Norges Bank (0.97%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 2/26/2024 by MarketBeat.com Staff

From Our Partners